Insider Trading & Ownership of Anna Protopapas

Location
Cambridge, MA
Summary
The estimated net worth of Anna Protopapas is at least $512,201 dollars as of 06 Jan 2026. Anna Protopapas is the Director of Nuvalent, Inc. and owns shares of Nuvalent, Inc. (NUVL) stock worth about $384.7K. Anna Protopapas is the Director of Dicerna Pharmaceuticals Inc and owns shares of Dicerna Pharmaceuticals Inc stock worth about $127.5K.
Signature
/s/ Anna Protopapas
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Anna Protopapas and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Quick Takeaways

  • Anna Protopapas has 3 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $512,201.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Nuvalent, Inc. ($384,714).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Anna Protopapas

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
NUVL Nuvalent, Inc. Director $384,714 18 Jun 2025
DRNA Dicerna Pharmaceuticals Inc Director $127,487 03 Jun 2021
MRSN Mersana Therapeutics, Inc. Director $0 06 Jan 2026

Insider Transactions Reported by Anna Protopapas:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .